Cardiovascular News’ top 10 most popular stories of November 2021


Featuring stories from the Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2021, 4–6 November, Orlando USA and virtual), American Heart Association’s Scientific Sessions 2021 (AHA 2021; 13–15 November, virtual) and PCR London Valves (21–23 November, London, UK and virtual), November was a bumper month of conference coverage on Cardiovascular News. Catch up on the most read stories here.

1. Profile: Mirvat Alasnag
Mirvat Alasnag is the Gulf region’s first female interventional cardiologist. Currently the director of the Catheterization Laboratory at King Fahd Armed Forces Hospital (Jeddah, Saudi Arabia). She talks to Cardiovascular News about her career in medicine and the challenges for women in the interventional cardiology field.

2. First clinical data back use of Jenavalve TAVI system in patients with aortic regurgitation
First clinical results of transcatheter aortic valve implantation (TAVI) using the Jenavalve system (Jenavalve) in patients with severe aortic regurgitation show that the device is safe and efficient in high-risk patients, significantly improves New York Heart Association (NYHA) classification.

3. CABG “remains the treatment of choice” for complex, three-vessel coronary artery disease
Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) did not meet non-inferiority for one-year adverse events compared to coronary artery bypass grafting (CABG) in patients with three-vessel coronary artery disease, primary results of the FAME 3 (Fractional flow reserve versus angiography for multivessel evaluation) trial have shown.

4.TAVI in low-risk patients is cost effective, PARTNER 3 finds
An economic analysis of data from the PARTNER 3 randomised trial, comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk, found that despite higher up-front procedural costs, at two-year follow-up, quality-adjusted life expectancy was greater and total costs were lower with TAVI.

5. Findings of meta-analysis “move the conversation forward” on left main revascularisation
A meta-analysis comparing percutaneous coronary intervention (PCI) using a drug-eluting stent (DES) to coronary artery bypass graft (CABG) surgery in patients with left main coronary artery disease has concluded there is no statistically significant difference between the two strategies in terms of mortality at five years.

6. “Promising” early data shared on alternatives to paclitaxel DCBs at TCT 2021
Early data presented at the Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2021; 4–6 November, Orlando, USA and virtual) suggest there may be a future for the use of sirolimus-coated balloons, offering an alternative to paclitaxel for the treatment of both in-stent restenosis and de novo lesions.

7. Five-year SURTAVI data show comparable performance for TAVI and SAVR on mortality, stroke
Five-year clinical and echocardiographic outcome data from the SURTAVI randomised trial comparing transcatheter aortic valve implantation (TAVI) using an early-generation device to surgical aortic valve replacement (SAVR) have shown no difference in all-cause mortality or stroke between the two procedures in patients at intermediate surgical risk.

8. Patients more likely to survive a cardiac arrest in the operating room than the cath lab
Patients who went into cardiac arrest in the cardiac cath lab were more likely to survive to hospital discharge than those who had a cardiac arrest in the intensive care unit (ICU), yet less likely to survive than those who had an arrest in the operating room (OR).

9. Two-year GALILEO data show comparable outcomes for TAVI with self-expanding or balloon-expandable valves according to physician discretion
Two-year findings of a post-hoc study from the GALILEO trial, investigating the clinical outcomes after successful transcatheter aortic valve implantation with a balloon-expandable or a self-expanding valve, suggest that there are comparable outcomes between the two devices.

10. Six-month RADIANCE-HTN TRIO results “open a window” for renal denervation
Six-month outcomes from the randomised RADIANCE-HTN TRIO trial, comparing endovascular ultrasound renal denervation to a sham procedure for treatment-resistant hypertension, demonstrate the additional effects of pharmacologic intervention with maintenance of a blood pressure-lowering effect of renal denervation at six months, according to investigators.


Please enter your comment!
Please enter your name here